A Randomized, Double-Blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 980 Compared with Trastuzumab in Subjects with HER2 Positive Early Breast Cancer

Trial Profile

A Randomized, Double-Blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 980 Compared with Trastuzumab in Subjects with HER2 Positive Early Breast Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Trastuzumab (Primary) ; Cyclophosphamide; Epirubicin; Paclitaxel
  • Indications Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms Lilac
  • Sponsors Amgen
  • Most Recent Events

    • 12 Sep 2017 Primary endpoint (Risk ratio (RR) of the incidence of pathologic complete response (pCR) in breast tissue and axillary lymph nodes) has been met as per the results presented at the 42nd European Society for Medical Oncology Congress.
    • 12 Sep 2017 Primary endpoint (Risk difference (RD) of the incidence of pathologic complete response (pCR) in breast tissue and axillary lymph nodes) has been met as per the results presented at the 42nd European Society for Medical Oncology Congress.
    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top